CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 86 resultados LastUpdate Última actualización 11/08/2020 [20:31:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 365 días/Published applications in the last 365 days



previousPage Página3 de 4 nextPage   por página


Novel coronavirus(2019-nCoV) ORF1ab gene nucleic acid detection kit

NºPublicación: CN111020064A 17/04/2020

Solicitante:

DA AN GENE CO LTD OF SUN YAT SEN UNIV

Resumen de: CN111020064A

The invention provides a novel coronavirus ORF1ab gene nucleic acid detection kit, and particularly discloses a kit for detecting the ORF1ab gene of the novel coronavirus and a method thereof, which have extremely high sensitivity and specificity.

traducir

Novel coronavirus N-gene nucleic acid detection kit

NºPublicación: CN111004870A 14/04/2020

Solicitante:

DA AN GENE CO LTD OF SUN YAT SEN UNIV

Resumen de: CN111004870A

The invention provides a novel coronavirus N-gene nucleic acid detection kit, and particularly discloses a kit and a method for detecting the N-gene nucleic acid of novel coronavirus 2019-nCoV, wherein the kit and the method have extremely high sensitivity and extremely high specificity.

traducir

Alcohol disinfection two-way sprayer for novel pneumonia

NºPublicación: CN210302020U 14/04/2020

Solicitante:

WEN JING

Resumen de: CN210302020U

The utility model discloses an alcohol disinfection two-way sprayer for novel pneumonia. The alcohol disinfection two-way sprayer comprises an alcohol disinfection spray bottle body, a bottle opening,a first suction pipe, a connecting opening, a pressure button, a first spray head, a protective cover, a second spray head, a second suction pipe and a handle. The alcohol disinfection sprayer has the beneficial effects that the alcohol disinfection sprayer is provided with two groups of spray heads, so that a user can disinfect himself/herself when using the alcohol disinfection sprayer to sprayand disinfect an infected person possibly carrying novel coronavirus infection, and the safety in use is effectively improved; a protective cover is further arranged and can effectively block propagation of the novel coronavirus, so that the safety in use is further improved; the device is simple in structure, reasonable in distribution, convenient to use and easy to popularize.

traducir

Adenovirus vector vaccine for preventing SARS-CoV-2 infection

NºPublicación: CN110974950A 10/04/2020

Solicitante:

GUANGZHOU NBIOMED PHARMACEUTICAL TECH CO LTD

Resumen de: CN110974950A

The invention discloses an adenovirus vector vaccine for preventing SARS-CoV-2 infection. The vaccine comprises a nucleic acid sequence as shown in SEQ ID NO: 1. According to a plurality of embodiments of the invention, the S protein nucleic acid sequence contained in the vaccine is easy to express in human cells, and generation of more S proteins can be induced, so the vaccine is expected to be used as a recombinant virus vaccine for preventing SARS-CoV-2 infection. According to a plurality of embodiments of the invention, the vaccine has good security.

traducir

Novel coronavirus visual constant-temperature rapid detection kit

NºPublicación: CN110982944A 10/04/2020

Solicitante:

INST ANIMAL SCIENCES CAAS

Resumen de: CN110982944A

The invention provides a novel coronavirus visual constant-temperature (nucleic acid extraction-free) rapid detection kit. According to the invention, a specific nucleic acid sequence of a novel coronavirus (2019-nCoV) is used as a target gene; LAMP amplification primers are designed; a novel coronavirus constant-temperature rapid nucleic acid amplification technology detection method is established on the basis of the advantages of high specificity, high sensitivity, simplicity and convenience of a loop-mediated isothermal amplification technology; and a visual constant-temperature novel coronavirus rapid detection kit is constructed on the basis of the detection method. The kit provided by the invention can effectively detect standard plasmids with a concentration of 5 copies/[mu]l, andhas a reaction time of only 30 minutes. The kit provided by the invention can achieve the purpose of quickly and accurately detecting the novel coronavirus, and has good application prospect.

traducir

Composition, kit and method for detecting and typing coronavirus, and application of composition

NºPublicación: CN110982942A 10/04/2020

Solicitante:

SANSURE BIOTECH INC

Resumen de: CN110982942A

The invention relates to the field of molecular biological detection, and more specifically to the field of coronavirus detection. The composition provided by the invention can be used for detecting and typing a novel coronavirus 2019-nCoV, a coronavirus 229E, a coronavirus NL63, a coronavirus OC43, a coronavirus HKU1, a coronavirus MERSr-CoV and a coronavirus SARSr-CoV. Meanwhile, the invention also provides a kit containing the composition, an application of the composition and a method for detecting and typing the coronavirus. The composition provided by the invention combines a fluorescentprobe method and a melting curve method, can simultaneously detect seven coronaviruses in one tube and perform typing, is low in cost, high in flux and less in time consumption, greatly improves thedetection efficiency, is simple and convenient to operate, and avoids false positive and environmental pollution caused by cross among samples through single-tube operation.

traducir

RT-PCR detection method and kit for novel coronavirus

NºPublicación: CN110982943A 10/04/2020

Solicitante:

DA AN GENE CO LTD OF SUN YAT SEN UNIV

Resumen de: CN110982943A

The invention provides a real-time fluorescence RT-PCR detection method and a kit for a novel coronavirus 2019-nCoV. Specifically, the invention discloses a kit and a method for detecting the nucleicacid of an E gene of the novel coronavirus 2019-nCoV. The kit and the method have extremely high sensitivity and specificity, and can remarkably improve the accuracy of virus identification.

traducir

Anti-coronavirus macleaya cordata benzylisoquinoline alkaloid and resveratrol composition and application thereof

NºPublicación: CN110960532A 07/04/2020

Solicitante:

JIN XIAOFEI

Resumen de: CN110960532A

The invention discloses an anti-coronavirus macleaya cordata benzylisoquinoline alkaloid and resveratrol composition and application thereof. The macleaya cordata benzylisoquinoline alkaloid and resveratrol composition is prepared from five compositions including sanguinarine, chelerythrine, protopine, alpha-allocryptoxine and trans-resveratrol. The macleaya cordata benzylisoquinoline alkaloid andresveratrol composition has unique binding activity on a coronavirus related protein target, has a remarkable anti-coronavirus effect, and is expected to become a raw material of a drug for treatingpneumonia caused by human infection of Covid-19 coronavirus especially when concerning to the inhibition effect on Covid-19 coronavirus. The composition can be used for preparing medicines or other products for resisting diseases caused by coronavirus infection.

traducir

Nucleotide acid sequences expressing SARS-CoV-2 virus antigen peptide and application of nucleotide acid sequences

NºPublicación: CN110951756A 03/04/2020

Solicitante:

GUANGZHOU NBIOMED MEDICINE TECH CO LTD

Resumen de: CN110951756A

The invention discloses nucleotide acid sequences expressing SARS-CoV-2 virus antigen peptide and application of the nucleotide acid sequences. The nucleotide acid sequence comprise SEQ ID NO:1, SEQ ID NO:2 or a sequence with at least 90% homology. Nucleotide acid sequences in embodiments can be effectively expressed in human cells to produce corresponding polypeptides and produce corresponding immune protection reactions by induction, and are expected to be developed into SARS-CoV-2 vaccines.

traducir

COVID-19 knockout DNA CoVID-19 suitable triple knockout DNAi remedy

NºPublicación: KR20200032050A 25/03/2020

Solicitante:

KIM SEUNG CHAN [KR]

Resumen de: KR20200032050A

The present invention relates to a diagram with respect to a triple knockout DNA antisense oligomer for coronavirus epidemic originated from Wuhan, China. The virus based on Wuhan pneumonia virus sequencing which has already progressed on January 13 is investigated, and a prescription is included. A single strand patent was secured in 2012. A liposome transports a single strand DNA for intracellular procurement and is coupled to three parts to remove virus genome.

traducir

Bovine coronavirus chimeric antigen and aurosol immunochromatographic assay test strip for detecting bovine coronavirus antibody

NºPublicación: CN110894217A 20/03/2020

Solicitante:

UNIV CHINA AGRICULTURAL

Resumen de: CN110894217A

The invention relates to the technical field of immunodetection, and discloses a bovine coronavirus chimeric antigen and an aurosol immunochromatographic assay test strip for detecting a bovine coronavirus antibody. The sequence of the chimeric antigen is shown as SEQID NO:1. The invention provides a novel bovine coronavirus chimeric antigen. When being used as a detection antigen of the bovine coronavirus antibody, the bovine coronavirus chimeric antigen has high specificity, repeatability and accuracy, and can be applied to associated immunochromatographic assay detection products. The results are visual and can be judged through naked eyes, the bovine coronavirus antibody in serum can be quickly and specially detected, and the problem for quick rapid diagnosis of diarrhoea of calves ina scaleable milk cow farm is solved. The bovine coronavirus chimeric antigen has high use value, and grass-roots unit promotion and application are facilitated.

traducir

Prescription capable of treating pneumonia caused by 2019-nCoV (a novel coronavirus) infection and application thereof

NºPublicación: CN110870402A 06/03/2020

Solicitante:

GE YOUWEN

Resumen de: CN110870402A

The invention relates to traditional Chinese medicine compositions, and specifically discloses a prescription capable of treating pneumonia caused by 2019-nCoV (a novel coronavirus) infection as wellas application thereof. The prescription capable of treating the pneumonia caused by the 2019-nCoV infection comprises the following traditional Chinese medicine materials as raw materials in parts byweight: 9 parts of ephedra, 6 parts of roasted liquorice roots, 9 parts of apricot kernels, 15-30 parts of raw gypsum, 9 parts of cassia twigs, 9 parts of oriental waterplantain rhizome, 9 parts of zhuling, 9 parts of white atractylodes rhizomes, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of baical skullcap roots, 9 parts of ginger processed pinellia tubers, 9 parts of fresh ginger, 9 parts of aster, 9 parts of common coltsfoot flowers, 9 parts of blackberry lily rhizome, 6 parts of manchurian wildginger, 12 parts of Chinese yams, 6 parts of immature orange fruits, 6 parts of dried orange peel, and 9 parts of wrinkled gianthyssop herb. In combination with symptom manifestation of the pneumonia caused by the 2019-nCoV infection, the invention adopts an optimized and integrated traditional Chinese medicine prescription, thereby achieving synergistic treatment effects. According to current treatment results of diagnosed patients of different ages in many provinces and regions, the prescription capable of treating the pneumonia caused by the 2019-nCoV infection has true

traducir

Isoxazole derivatives and preparation process thereof

NºPublicación: KR20200023034A 04/03/2020

Solicitante:

IL YANG PHARM CO LTD [KR]

WO_2020040343_PA

Resumen de: KR20200023034A

The present invention relates to: an isoxazole derivative compound of chemical formula 1, useful as a substance for treating s respiratory viral infection disease coronavirus, in particular, Middle East respiratory syndrome coronavirus (MERS-CoV); a pharmaceutically acceptable derivative thereof; a manufacturing method thereof; and a pharmaceutical composition for treating coronavirus infection, which contains the compound as an active component.

traducir

ISOXAZOLE DERIVATIVES AND PREPARATION PROCESS THEREOF

NºPublicación: WO2020040343A1 27/02/2020

Solicitante:

IL YANG PHARM CO LTD [KR]

KR_20200023034_A

Resumen de: WO2020040343A1

The present invention relates to an isoxazole derivative compound of Formula (1) useful as a substance for treating respiratory viral infectious disease caused by coronavirus, in particular, Middle East respiratory syndrome-coronavirus (MERS-CoV); a pharmaceutically acceptable derivative thereof; a preparation process of the same; and a pharmaceutical composition for the treatment of coronavirus infection comprising the above comopund as an active ingredient.

traducir

S A monoclonal antibody against S protein of MERS-CoV and use of the same

NºPublicación: KR20200020411A 26/02/2020

Solicitante:

INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIV [KR]

WO_2020036403_PA

Resumen de: KR20200020411A

The present invention relates to a monoclonal antibody which specifically recognizes spike protein of Middle East respiratory syndrome coronavirus (MERS-CoV) or a portion of the protein; or a functional fragment thereof. The monoclonal antibody or the functional fragment thereof includes one polypeptide sequence selected from a group consisting of the below polypeptide sequence. The monoclonal antibody comprises: a heavy chain including CDR1 region described as sequence number 1, CDR2 region described as sequence number 2, and CDR3 region described as sequence number 3; and a light chain including CDR1 region described as sequence number 4, CDR2 region described as sequence number 5, and CDR3 area described as sequence number 6. Therefore, the monoclonal antibody of the present invention can be applied to the diagnosis and treatment for the infection caused by MERS-CoV.

traducir

MONOCLONAL ANTIBODY AGAINST S PROTEIN OF MERS-CORONAVIRUS, AND USE OF SAME

NºPublicación: WO2020036403A1 20/02/2020

Solicitante:

INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIV [KR]

KR_20200020411_A

Resumen de: WO2020036403A1

The present invention relates to a monoclonal antibody capable of specifically recognizing a spike protein of Middle East respiratory syndrome coronavirus (MERS-CoV) or a portion of the protein, or a functional fragment of the monoclonal antibody; and to a use of same, wherein the monoclonal antibody or a functional fragment thereof is characterized by comprising any one polypeptide sequence selected from the group consisting of the following polypeptide sequences, and wherein the monoclonal antibody consists of a heavy chain comprising a CDR1 region represented by SEQ ID NO: 1, a CDR2 region represented by SEQ ID NO: 2, and a CDR3 region represented by SEQ ID NO: 3, and a light chain comprising a CDR1 region represented by SEQ ID NO: 4, a CDR2 region represented by SEQ ID NO: 5, and a CDR3 region represented by SEQ ID NO: 6.

traducir

Fluorescent quantitative PCR detection method of human coronavirus and respiratory syncytial virus and application thereof

NºPublicación: CN110724764A 24/01/2020

Solicitante:

INST PATHOGEN BIOLOGY CAMS

Resumen de: CN110724764A

The invention provides primers and probes or a combination thereof of fluorescent quantitative PCR that can be used to detect diseases caused by human coronavirus and respiratory syncytial virus. In aspecific embodiment, the sequences of the primers and probes are as shown in SEQIDNOs: 1-3, and/or as shown in SEQIDNOs: 4-6, and/or as shown in SEQIDNOs: 7-9. The invention also provides applicationof the primers and probes or the combination thereof to preparation of reagents for detecting human coronavirus OC43, human coronavirus HKU1 and/or respiratory syncytial virus RSVB in samples.

traducir

New coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein

NºPublicación: CN110616198A 27/12/2019

Solicitante:

UNIV TSINGHUA
INST PASTEUR SHANGHAI CAS

Resumen de: CN110616198A

The present invention discloses a new coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein. The recombinant adenovirus is obtained by transfecting an adenovirus packaging cell with a recombinant plasmid and then performing cell culture; the recombinant plasmid is obtained by inserting a specific DNA molecule into a delta-E1 region of a chimpanzee adenovirus vector AdC68; the specific DNA molecule has a full-length MERS-CoV Spike protein encoding gene; and the adenovirus packaging cell has an adenovirus E1 gene. The present invention also protectsthe recombinant adenovirus expressing the full-length MERS-CoV Spike protein; and a starting strain of the recombinant adenovirus is chimpanzee adenovirus type 68 or non-replicating chimpanzee adenovirus type 68. The developed vaccine against the new coronavirus MERS-CoV has important theoretical guidance value and broad application prospects, and provides a possibility for radical cure of MiddleEast respiratory syndrome.

traducir

IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS)

NºPublicación: RU2709659C1 19/12/2019

Solicitante:

FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ ISSLEDOVATELSKIJ TSENTR EPIDEMIOLOG [RU]

Resumen de: RU2709659C1

FIELD: biotechnology.SUBSTANCE: invention refers to biotechnology, immunology and virology. Described is an immunobiological agent based on human recombinant adenovirus 5-th serotype or recombinant human adenovirus 26-th serotype, containing optimized expression in mammal cells consensus sequence of complete protective antigen S of MERS virus on the basis of sequences of protein S genes of modern strains of virus MERS 2015-2017 years with sequence SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5. Method for using the immunobiological agent for inducing specific immunity to MERS-CoV. Method of using the immunobiological agent consists in the sequential introduction into the body of mammals of two different immunobiological agents based on human recombinant adenovirus of 5-th serotype or two different immunobiological agents based on human recombinant adenovirus of 26-th serotype with a period of more than 1 week, for inducing specific immunity to MERS-CoV. There is also developed a method for using the immunobiological agent consisting in consecutive introduction into an organism of mammals of any of the immunobiological agents based on human recombinant adenovirus of 5-th serotype and any of the immunobiological preparations based on human recombinant adenovirus 26-th serotype with a period of more than 1 week, for the induction of specific immunity to MERS-CoV, or in consecutive introduction into organism of mammals of any of immunobiological agents on

traducir

HBD2human beta-defensin 2 A composition for preventing or treating MERS-CoV virus comprising HBD2 human beta-defensin 2 or an fusion protein comprising epitope protein of MERS-CoV virus and the HBD2

NºPublicación: KR20190134578A 04/12/2019

Solicitante:

NAT UNIV CHONBUK IND COOP FOUND [KR]

Resumen de: KR20190134578A

The present invention relates to a composition for preventing or treating MERS-coronavirus comprising human beta-defensin 2 (HBD2) or epitope protein of MERS virus fused with a gene. In other words, HBD2 has effects of antiviral activity, innate immunity enhancement, and immunity enhancement.

traducir

MERS CORONAVIRUS VACCINE

NºPublicación: US2019351048A1 21/11/2019

Solicitante:

CUREVAC AG [DE]

WO_2018115527_A2

Resumen de: US2019351048A1

The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.

traducir

Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein

NºPublicación: US2019351049A1 21/11/2019

Solicitante:

REGENERON PHARMA [US]

BR_112016025009_A2

Resumen de: US2019351049A1

The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.

traducir

USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS

NºPublicación: US2019336456A1 07/11/2019

Solicitante:

ABIOGEN PHARMA SPA [IT]

MX_2019000645_A

Resumen de: US2019336456A1

The use of xibornol as a virucidal agent is described in the prophylactic or therapeutic treatment of an infection caused by one or more viruses, said viruses comprising at least one of human Adenovirus, human Rhinovirus, human Coronavirus, and a combination thereof.

traducir

IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION

NºPublicación: US2019328865A1 31/10/2019

Solicitante:

NEW YORK BLOOD CENTER INC [US]

Resumen de: US2019328865A1

Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.

traducir

An anti-MERS-CoV monoclonal antibody and use of the same

Nº publicación: KR20190122283A 30/10/2019

Solicitante:

INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIV [KR]

Resumen de: KR20190122283A

The present invention relates to a monoclonal antibody that specifically recognizes a protein of MERS-coronavirus (MERS-CoV) or a portion of the protein, or a functional fragment thereof, and uses thereof, wherein the monoclonal antibody or functional fragment thereof comprises any one polypeptide sequence selected from the group consisting of the following polypeptide sequences: a heavy chain comprising a CDR1 region as depicted in SEQ ID NO: 1, a CDR2 region as depicted in SEQ ID NO: 2 and a CDR3 region as depicted in SEQ ID NO: 3; and a light chain comprising a CDR1 region as depicted in SEQ ID NO: 4, a CDR2 region as depicted in SEQ ID NO: 5 and a CDR3 region as depicted in SEQ ID NO: 6.

traducir

previousPage Página3 de 4 nextPage por página

punteroimgVolver